Relationship between memory performance and β-amyloid deposition at different stages of Alzheimer's disease

Neurodegenerative Diseases

Volumn 10, Issue 1-4, 2012, Pages 141-144

  Chételat, Gaël ^a,f   Villemagne, Victor L ^a,b,c   Pike, Kerryn E ^a,b,d   Ellis, Kathryn A ^c   Ames, David ^e   Masters, Colin L ^b   Rowe, Christopher C ^a,c  

^a AUSTIN HEALTH   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d LA TROBE UNIVERSITY   (Australia)

^e NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^f UNIVERSITÉ DE CAEN   (France)

Author keywords

Amyloid deposition; Alzheimer's disease; Memory decline

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B;

ADULT; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EPISODIC MEMORY; GRAY MATTER; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NEOCORTEX; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; WHITE MATTER;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; ATROPHY; BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MEMORY DISORDERS; POSITRON-EMISSION TOMOGRAPHY; THIAZOLES;

EID: 84860220950     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000334295     Document Type: Article

References (23)

1. Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT: Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 1995; 38: 254-259.
2. Mega MS, Dinov ID, Porter V, Chow G, Reback E, Davoodi P, O'Connor SM, Carter MF, Amezcua H, Cummings JL: Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Arch Neurol 2005; 62: 721-728.
3. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319.
4. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE: Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65: 1509-1517.
5. Hedden T, Van Dijk KRA, Becker JA, Mehta A, Sperling RA, Johnson KA, Buckner RL: Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci 2009; 29: 12686-12694.
6. Jack CR, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC: 11 C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131: 665-680.
7. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon- Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL: Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31: 1275-1283.
8. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, Aizenstein HJ, Cohen AD, Weissfeld LA, Mathis CA, Klunk WE, De-Kosky ST: Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009; 65: 557-568.
9. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Långström B, Nordberg A: PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29: 1456-1465.
10. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ, Alzheimer's Disease Neuroimaging Initiative: Episodic memory loss is related to hippocampal- mediated beta-amyloid deposition in elderly subjects. Brain 2009; 132: 1310-1323.
11. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC: Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007; 130: 2837-2844.
12. Rentz DM, Locascio JJ, Becker JA, Moran EK, Eng E, Buckner RL, Sperling RA, Johnson KA: Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 2010; 67: 353-364.
13. Forsberg A, Almkvist O, Engler H, Wall A, Långström B, Nordberg A: High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res 2010; 7: 56-66.
14. Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, Marshall G, Hyman BT, Selkoe DJ, Hedden T, Buckner RL, Becker JA, Johnson KA: Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009; 63: 178-188.
15. Storandt M, Mintun MA, Head D, Morris JC: Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol 2009; 66: 1476-1481.
16. Fripp J, Bourgeat P, Acosta O, Raniga P, Modat M, Pike KE, Jones G, O'Keefe G, Masters CL, Ames D, Ellis KA, Maruff P, Currie J, Villemagne VL, Rowe CC, Salvado O, Ourselin S: Appearance modeling of 11 C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. Neuroimage 2008; 43: 430-439.
17. Tolboom N, van der Flier WM, Yaqub M, Koene T, Boellaard R, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN: Differential association of [ 11 C]PIB and [ 18 F] FDDNP binding with cognitive impairment. Neurology 2009; 73: 2079-2085.
18. Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, Ackermann U, Cowie TF, Currie J, Chan SG, Jones G, Tochon-Danguy H, O'Keefe G, Masters CL, Rowe CC: Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2008; 46: 1688-1697.
19. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, Hotton G, Cutler D, Fox N, Kennedy A, Rossor M, Brooks DJ: Amyloid, hypometabolism, and cognition in Alzheimer disease: an [ 11 C]PIB and [ 18 F]FDG PET study. Neurology 2007; 68: 501-508.
20. Furst AJ, Rabinovici GD, Rostomian AH, Steed T, Alkalay A, Racine C, Miller BL, Jagust WJ: Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol Aging, E-pub ahead of print.
21. Resnick SM, Sojkova J, Zhou Y, An Y, Ye W, Holt DP, Dannals RF, Mathis CA, Klunk WE, Ferrucci L, Kraut MA, Wong DF: Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [ 11 C]PiB. Neurology 2010; 74: 807-815.
22. Pike KE, Ellis KA, Villemagne VL, Good N, Chételat G, Ames D, Szoeke C, Laws SM, Verdile G, Martins RN, Masters CL, Rowe CC: Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia 2011; 49: 2384-2390.
23. Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, O'Keefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC, AIBL Group: Independent contribution of temporal A3β deposition to memory decline in the predementia phase of Alzheimer's disease. Brain 2011; 134: 798-807.